



11th Symposium on Glycosaminoglycans

September 17th-19th, 2003

Organizers:

Job Harenberg,

4th Department of Medicine Faculty of Clinical Medicine Mannheim

Benito Casu,

**„G. Ronzoni“ Institute for Chemical and Biochemical Research,
Milan**

Jürgen Jacob,

Baxter Deutschland, GmbH, Hyland Immuno Division Heidelberg

|

Main topics

Anticoagulants

argatroban, dermatansulfate, glycosaminoglycans, heparins, hirudins, low-molecular-weight heparins, new antithrombotic drugs, pentasaccharide, thrombin inhibitors

Characterization of Glycosaminoglycans

Anticoagulant assays, nuclear magnetic resonance, new biological assays, standardization and harmonization of methods

Structure-function relationship

Drug interactions of anticoagulants, glycosaminoglycans and platelet factor 4, glycosaminoglycans and growth factors, glycosaminoglycans and inflammation, heparin-induced thrombocytopenia, protein- glycosaminoglycan interactions
Glycosaminoglycans in renal disease

Polysaccharides and biomaterials

Coating of stents, coating of biological materials

Clinical studies

Deep venous thrombosis and pulmonary embolism, glycosaminoglycans, ischemic stroke, myocardial infarction, new indications, prolonged prophylaxis of venous thromboembolism, pentasaccharides, thrombin inhibitors

Scientific board

Breddin HK, Casu B, Gambaro G, Harenberg J, Palumbo M, F. van der Woude

Faculty

Alban S, Baici A, Kirchmaier C, Markwardt F, Naggi A, Nowak G, Petitou M, Presta M, Stemberger A, Wenzel E

Welcome address:

Casu B, Milano, Harenberg J, Mannheim

Preliminary list of lecturers

Wednesday Afternoon Session Size and activity

Moderators: *Alban S, Kiel, Breddin H-K, Frankfurt*

- a) Minimum GAG size to elicit antithrombotic activity (*M. Petitou, Toulouse*)
- b) Absolute molecular weight of heparins (*G. Torri, Milano*)
- c) Ultra-low-molecular weight heparins (*V. Laux, Frankfurt*)
- d) Anticoagulant heparan sulfate proteoglycans (*A. De Agostini, Geneve*)
- e) DNA heptamers (*M. Palumbo, Padova*)
- f) Binding of glycosaminoglycans to foreign surfaces (*A. Stemberger, Munich*)

Thursday Morning Session LMW-heparins

Moderators: *Casu B, Milano, Wenzel E, Homburg/Saar, Stemberger A, Munich*

- a) In-depth characterization of Enoxaheparin (*C. Viskov, Paris*)
- b) Rationally-designed LMW-heparins (*G. Venkataraman, Boston*)
- c) Generic versions of branded LMW-heparins. Pros and cons. (*J. Fareed, Maywood*)

Thursday Afternoon Session Glycosaminoglycan-induced inhibition of cancer progression and metastasis

Moderators: *Presta M, Brescia, Calatzis A, Munich, Gulba D, Düren*

- a) Targeting growth factors (*R. Sasisekharan, Boston*)
- b) Targeting heparanase (*I. Vlodavsky, Jerusalem*)
- c) Targeting P-selectin (*L. Borsig, San Diego*)
- d) LMWH and cancer survival: emerging clinical evidence (*A.Kakkar, London*)

Friday Morning Session Clinical assessment of glycosaminoglycans

Moderators: *Nowak G, Jena, Harenberg J, Mannheim*

Clinical assessment of glycosaminoglycans (*J. Harenberg, Mannheim*)
Comparison with other antithrombotics (*F. Markwardt, Erfurt*)
Interaction with other antithrombotics (*T. Fenyvesi, Mannheim*)
Documentation of rare side effects of glycosaminoglycans (*E. Wenzel, Wien*)

Friday Afternoon Session New therapeutic targets

Minisymposium : Glycosaminoglycans in renal disease

Moderators: *G. Gambaro, Padua; van der Woude, Mannheim*

Proteoglycan and glycosaminoglycan composition in renal disease (*H.J.M. Berden, Nijmegen*)
Proteoglycans and glycosaminoglycans vs cytokines in renal disease (*J. Floege, Aachen*)
Proteoglycans and glycosaminoglycans vs monocytes in inflammation and renal disease (*F. van der Woude, Mannheim*)
Proteoglycans and glycosaminoglycans vs oxidative stress in inflammation and renal disease (*E. Schleicher, Tübingen*)
Proteoglycans and glycosaminoglycans in the maturation of immunocompetent cells (*C. Termeer, Freiburg*)
Prophylaxis of progression of nephropathy in patients with renal impairment by subcutaneous Nadroheparin (*B. Kovaliw, Lviv, Ukraine*)
Treatment with glycosaminoglycans: a new strategy to improve outcome after kidney transplantation? (*C. Braun, Mannheim*)

Sponsors:

Astra Zeneca, Wedel, Germany
Aventis Glycochemistry, Vitry Sur Seine, France
Aventis Pharma Deutschland, Frankfurt, Germany
Aventis Pharma, US
Baxter Deutschland GmbH, Heidelberg, Germany
Celltech GmbH & Co.KG, Essen, Germany
CONCOR, Milano, Italy
DFG, Deutsche Forschungsgemeinschaft, Bonn, Germany
Gentium, Villa Guardia, Italy
Italfarmaco, Cinisello Balsamo, Italy
Laboratorio Derivati Organici (LDO), Trino Vercellese, Italy
Nicox Research, Sophia Antipolis, France
Opocrin Biofarmaci, Corlo di Formingine, Italy
Pentapharm Ltd. Basel, Switzerland
Pharmacia GmbH, Erlangen
Sanofi-Synthelabo, Milano, Germany
Sigma-Tau, Pomezia, Italy

General Information

Social Program

Wednesday, September 17, 2003

13.00 -14.00: Lunch in Villa Vigoni
19.00: Dinner in Villa Vigoni

Thursday, September 18, 2003

8.00-9.00: Breakfast
13.00 -14.00: Lunch in Villa Vigoni
19.00: Dinner in Villa Vigoni

Friday, September 19, 2003

8.00-9.00: *Breakfast*
12.30-13.30: *Lunch in Villa Vigoni*
Departure: *after lunch*

Location of the Symposium:

"Villa Vigoni e.V."
Via Giulio Vigoni 1
Loveno di Menaggio
I-22017 Menaggio (Como)
Tel.: +39-0344/361 11
Fax: +39-0344/36 12 10
E-mail: segretaria.vv@villavigoni.it
Internet: <http://www.villavigoni.it>

Registration: Wednesday, September 17, 2003